These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22431574)

  • 1. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
    Jabbour E; Cortes J; Nazha A; O'Brien S; Quintas-Cardama A; Pierce S; Garcia-Manero G; Kantarjian H
    Blood; 2012 May; 119(19):4524-6. PubMed ID: 22431574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib.
    Tao Z; Liu B; Zhao Y; Wang Y; Zhang R; Han M; Zhang L; Li C; Ru K; Mi Y; Wang J
    Leuk Res; 2014 Sep; 38(9):1030-5. PubMed ID: 24996976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
    Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
    Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population.
    Yahng SA; Jang EJ; Choi SY; Lee SE; Kim SH; Kim DW
    Int J Hematol; 2014 Aug; 100(2):132-40. PubMed ID: 24879034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
    Shah NP; Kim DW; Kantarjian H; Rousselot P; Llacer PE; Enrico A; Vela-Ojeda J; Silver RT; Khoury HJ; Müller MC; Lambert A; Matloub Y; Hochhaus A
    Haematologica; 2010 Feb; 95(2):232-40. PubMed ID: 20139391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
    Radich JP; Kopecky KJ; Appelbaum FR; Kamel-Reid S; Stock W; Malnassy G; Paietta E; Wadleigh M; Larson RA; Emanuel P; Tallman M; Lipton J; Turner AR; Deininger M; Druker BJ
    Blood; 2012 Nov; 120(19):3898-905. PubMed ID: 22915637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
    Jabbour E; Kantarjian H; O'Brien S; Shan J; Garcia-Manero G; Wierda W; Ravandi F; Borthakur G; Rios MB; Cortes J
    Blood; 2011 Feb; 117(6):1822-7. PubMed ID: 21030554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients.
    Yamamoto E; Fujisawa S; Hagihara M; Tanaka M; Fujimaki K; Kishimoto K; Hashimoto C; Itabashi M; Ishibashi D; Nakajima Y; Tachibana T; Kawasaki R; Kuwabara H; Koharazawa H; Yamazaki E; Tomita N; Sakai R; Fujita H; Kanamori H; Ishigatsubo Y
    Cancer Sci; 2014 Jan; 105(1):105-9. PubMed ID: 24450386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.
    Petzer AL; Fong D; Lion T; Dyagil I; Masliak Z; Bogdanovic A; Griskevicius L; Lejniece S; Goranov S; Gercheva L; Stojanovic A; Peytchev D; Tzvetkov N; Griniute R; Stanchev A; Grubinger T; Kwakkelstein M; Schuld P; Gastl G; Wolf D
    Haematologica; 2012 Oct; 97(10):1562-9. PubMed ID: 22511495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
    Sasaki K; Kantarjian HM; Jain P; Jabbour EJ; Ravandi F; Konopleva M; Borthakur G; Takahashi K; Pemmaraju N; Daver N; Pierce SA; O'Brien SM; Cortes JE
    Cancer; 2016 Jan; 122(2):238-48. PubMed ID: 26479889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation.
    Kim D; Goh HG; Kim SH; Choi SY; Park SH; Jang EJ; Kim DW
    Int J Hematol; 2012 Jul; 96(1):47-57. PubMed ID: 22610512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
    Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
    Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chronic myeloid leukemia 2008].
    Cervantes F
    Med Clin (Barc); 2008 Nov; 131(17):658-9. PubMed ID: 19087793
    [No Abstract]   [Full Text] [Related]  

  • 14. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
    Pemmaraju N; Kantarjian H; Shan J; Jabbour E; Quintas-Cardama A; Verstovsek S; Ravandi F; Wierda W; O'Brien S; Cortes J
    Haematologica; 2012 Jul; 97(7):1029-35. PubMed ID: 22271898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
    J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Ota S; Matsukawa T; Yamamoto S; Ito S; Shindo M; Sato K; Kondo T; Kohda K; Sakai H; Mori A; Takahashi T; Ikeda H; Kuroda H; Haseyama Y; Yamamoto M; Sarashina T; Yoshida M; Kobayashi R; Nishio M; Ishihara T; Hirayama Y; Kakinoki Y; Kobayashi H; Fukuhara T; Imamura M; Kurosawa M
    Eur J Haematol; 2018 Jul; 101(1):95-105. PubMed ID: 29660177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.
    Daghistani M; Marin D; Khorashad JS; Wang L; May PC; Paliompeis C; Milojkovic D; De Melo VA; Gerrard G; Goldman JM; Apperley JF; Clark RE; Foroni L; Reid AG
    Blood; 2010 Dec; 116(26):6014-7. PubMed ID: 20855863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.
    Latagliata R; Ferrero D; Iurlo A; Cavazzini F; Castagnetti F; Abruzzese E; Fava C; Breccia M; Annunziata M; Stagno F; Tiribelli M; Binotto G; Mansueto G; Gozzini A; Russo S; Cavalli L; Montefusco E; Gugliotta G; Cedrone M; Russo Rossi A; Avanzini P; Pregno P; Mauro E; Spadea A; Celesti F; Giglio G; Isidori A; Crugnola M; Calistri E; Sorà F; Storti S; D'Addosio A; Rege-Cambrin G; Luciano L; Alimena G
    Drugs Aging; 2013 Aug; 30(8):629-37. PubMed ID: 23681399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
    Kantarjian H; Pasquini R; Lévy V; Jootar S; Holowiecki J; Hamerschlak N; Hughes T; Bleickardt E; Dejardin D; Cortes J; Shah NP
    Cancer; 2009 Sep; 115(18):4136-47. PubMed ID: 19536906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
    Hochhaus A; Müller MC; Radich J; Branford S; Kantarjian HM; Hanfstein B; Rousselot P; Kim DW; Lipton JH; Bleickardt E; Lambert A; Hughes TP
    Leukemia; 2009 Sep; 23(9):1628-33. PubMed ID: 19641527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.